Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.

Even though from a biological perspective, activating mutations would be expected to have similar effects irrespective of the specific mutation, the KRAS models at most only showed a trend for the totality of KRAS mutations in predicting a reduced risk of a PFS event, remaining non-significant overall.

also in 53,322 other papers